
|Videos|December 27, 2022
Dr. Talwar on drug program’s impact on urologic medications
Author(s)Urology Times staff
“I just hope that people are as enthusiastic about this new company, as [I] and my coauthors are,” says Ruchika Talwar, MD.
Advertisement
In this video, Ruchika Talwar, MD, shares the take-home message from the recent Journal of Urology paper, “Urologic Drug Price Stewardship – Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model.” Talwar is a urologic oncology fellow at Vanderbilt University Medical Center in Nashville, Tennessee.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Initial prostate cancer presentation, family history linked to survival in mCRPC
2
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
3
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
4
AI system links surgical gestures with postoperative outcomes
5












